Gassert Chad's Form 4 filing
Ani Pharmaceuticals IncANIP · filed Oct 3, 2023
- Accession no.
- 0001871002-23-000009
- Filed
- Oct 3, 2023
- Trade date
- Oct 2, 2023
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Checked
This filing lists 1 non-derivative transaction. Open-market sales total $1.13M. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Gassert ChadCIK 0001871002 | Officer (SVP - CORP. DEV. & STRATEGY) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Oct 2, 2023 | Common Stock | SSaleDisposed | −20,000 | $56.48F2 | −$1,129,600 | 293,226 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
Reflects the weighted average price of sales on October 2, 2023. The shares were sold in multiple transactions at prices ranging from $55.90 to $57.66, inclusive.
Referenced by the price of 1 transaction in Table I.